{
  "first_published_at": "2010-11-10", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON099862", 
  "title": "Memantine pump device (Ebixa): risk of medication errors", 
  "tags": "{\"parsed_therapeutic\": [\"neurology\", \"psychiatry\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Neurology\", \"Psychiatry\"]}", 
  "_document_number": 176, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "neurology", 
    "psychiatry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Memantine pump device (Ebixa): risk of medication errors</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: November 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Several cases of administration error resulting in overdose with the new memantine pump device have been reported. The medication errors resulted from confusion between doses delivered by the new pump device and doses delivered by the dropper. Four actuations of the pump device is equivalent to 40 drops delivered by the dropper device. Healthcare professionals should be aware that there are differences in dose delivery between the pump device and dropper device for memantine.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Several cases of administration error resulting in overdose with the new memantine pump device have been reported. The medication errors resulted from confusion between doses delivered by the new pump device and doses delivered by the dropper. Four actuations of the pump device is equivalent to 40 drops delivered by the dropper device. Healthcare professionals should be aware that there are differences in dose delivery between the pump device and dropper device for memantine.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Memantine (Ebixa) is indicated for the treatment of patients with moderate to severe Alzheimer&rsquo;s disease, and tablets and an oral solution have been available since 2002. A pump device was introduced in March 2010 and replaces memantine oral solution administered by a dropper, which is being phased out by February 2011.</p><h2>Risk of medication errors and accidental overdose</h2><p>Up to Aug 9, 2010, seven cases of administration errors with the pump device have been reported worldwide. One patient was admitted to hospital and recovered, and two patients experienced somnolence, which is listed in the Summary of Product Characteristics as a possible adverse reaction associated with overdose. The remaining patients did not report any side effects.</p><p>The medication errors resulted from confusion between doses delivered by the new pump device and doses delivered by the dropper. Dosing for memantine devices is as follows:</p><p><strong>Pump device:</strong></p><ul>\r\n\t\t\t<li>One actuation of the pump device delivers 0.5 mL of solution, corresponding to 5 mg memantine. The maximum daily dose is 20 mg (ie, four pump actuations)</li></ul><p><strong>Old dropper device (being phased out):</strong></p><ul>\r\n\t\t\t<li>The dropper device delivers 0.5 mg/drop and the maximum daily dose of 20 mg is achieved with 40 drops</li></ul><p>Healthcare professionals should be aware of the correct use and administration of memantine pump device as outlined in the Summary of Product Characteristics. Healthcare professionals should also advise patients and their carers to carefully read the Patient Information Leaflet for memantine oral solution delivered by a pump device.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><br>\r\n\t\t\t\t<strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>There are differences in dose delivery between the pump device and dropper device for memantine</li>\r\n\t\t\t\t<li>One actuation of the pump device delivers 0.5 mL of solution, corresponding to 5 mg memantine. The maximum daily dose is 20 mg or four pump actuations, whereas 40 drops could be given with the dropper</li>\r\n\t\t\t\t<li>Please be vigilant regarding dose delivery for memantine products, particularly during the transition period from the dropper device to the new pump device. We request that you also advise patients and their caregivers:</li>\r\n\t\t\t\t<li style=\"LIST-STYLE-TYPE: none\">\r\n\t\t\t\t\t<ul>\r\n\t\t\t\t\t\t<li>how to use the new pump device to deliver the prescribed dose</li>\r\n\t\t\t\t\t\t<li>to carefully read the Patient Information Leaflet for memantine oral solution delivered by a pump device<br>        &nbsp;</li>\r\n\t\t\t\t\t</ul>\r\n\t\t\t\t</li>\r\n\t\t\t</ul></div><p>A <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON099712\" target=\"_blank\">letter has been sent to healthcare professionals</a> in October 2010 with information on this risk. Further information for patients can be found in the memantine Patient Information Leaflet.</p><h2>Reporting of suspected adverse reactions</h2><p>Please report any suspected adverse reactions associated with the use of&nbsp; memantine on a Yellow Card (<a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a>). Patients and caregivers can also report any suspected reactions to us via the Yellow Card Scheme.</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Nov 2010 vol 4, issue 4: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Memantine (Ebixa) is indicated for the treatment of patients with moderate to severe Alzheimer&#8217;s disease, and tablets and an oral solution have been available since 2002. A pump device was introduced in March 2010 and replaces memantine oral solution administered by a dropper, which is being phased out by February 2011.</p><h2>Risk of medication errors and accidental overdose</h2><p>Up to Aug 9, 2010, seven cases of administration errors with the pump device have been reported worldwide. One patient was admitted to hospital and recovered, and two patients experienced somnolence, which is listed in the Summary of Product Characteristics as a possible adverse reaction associated with overdose. The remaining patients did not report any side effects.</p><p>The medication errors resulted from confusion between doses delivered by the new pump device and doses delivered by the dropper. Dosing for memantine devices is as follows:</p><p><strong>Pump device:</strong></p><ul>\r\n\t\t\t<li>One actuation of the pump device delivers 0.5 mL of solution, corresponding to 5 mg memantine. The maximum daily dose is 20 mg (ie, four pump actuations)</li></ul><p><strong>Old dropper device (being phased out):</strong></p><ul>\r\n\t\t\t<li>The dropper device delivers 0.5 mg/drop and the maximum daily dose of 20 mg is achieved with 40 drops</li></ul><p>Healthcare professionals should be aware of the correct use and administration of memantine pump device as outlined in the Summary of Product Characteristics. Healthcare professionals should also advise patients and their carers to carefully read the Patient Information Leaflet for memantine oral solution delivered by a pump device.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><br>\r\n\t\t\t\t<strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>There are differences in dose delivery between the pump device and dropper device for memantine</li>\r\n\t\t\t\t<li>One actuation of the pump device delivers 0.5 mL of solution, corresponding to 5 mg memantine. The maximum daily dose is 20 mg or four pump actuations, whereas 40 drops could be given with the dropper</li>\r\n\t\t\t\t<li>Please be vigilant regarding dose delivery for memantine products, particularly during the transition period from the dropper device to the new pump device. We request that you also advise patients and their caregivers:</li>\r\n\t\t\t\t<li style=\"LIST-STYLE-TYPE: none\">\r\n\t\t\t\t\t<ul>\r\n\t\t\t\t\t\t<li>how to use the new pump device to deliver the prescribed dose</li>\r\n\t\t\t\t\t\t<li>to carefully read the Patient Information Leaflet for memantine oral solution delivered by a pump device<br>        &#160;</li>\r\n\t\t\t\t\t</ul>\r\n\t\t\t\t</li>\r\n\t\t\t</ul></div><p>A <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON099712\" target=\"_blank\">letter has been sent to healthcare professionals</a> in October 2010 with information on this risk. Further information for patients can be found in the memantine Patient Information Leaflet.</p><h2>Reporting of suspected adverse reactions</h2><p>Please report any suspected adverse reactions associated with the use of&#160; memantine on a Yellow Card (<a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a>). Patients and caregivers can also report any suspected reactions to us via the Yellow Card Scheme.</p><p>&#160;</p><p><em>Article citation: Drug Safety Update Nov 2010 vol 4, issue 4: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-11-01", 
  "date_last_modified": "2010-12-10", 
  "_assets": [], 
  "_item_id": 176, 
  "summary": "Several cases of administration error resulting in overdose with the new memantine pump device have been reported. The medication errors resulted from confusion between doses delivered by the new pump device and doses delivered by the dropper. Four actuations of the pump device is equivalent to 40 drops delivered by the dropper device. Healthcare professionals should be aware that there are differences in dose delivery between the pump device and dropper device for memantine.", 
  "body": "Article date: November 2010\n\nMemantine (Ebixa) is indicated for the treatment of patients with moderate to severe Alzheimer’s disease, and tablets and an oral solution have been available since 2002. A pump device was introduced in March 2010 and replaces memantine oral solution administered by a dropper, which is being phased out by February 2011.\n\n## Risk of medication errors and accidental overdose\n\nUp to Aug 9, 2010, seven cases of administration errors with the pump device have been reported worldwide. One patient was admitted to hospital and recovered, and two patients experienced somnolence, which is listed in the Summary of Product Characteristics as a possible adverse reaction associated with overdose. The remaining patients did not report any side effects.\n\nThe medication errors resulted from confusion between doses delivered by the new pump device and doses delivered by the dropper. Dosing for memantine devices is as follows:\n\nPump device:  \n  \n  * One actuation of the pump device delivers 0.5 mL of solution, corresponding to 5 mg memantine. The maximum daily dose is 20 mg (ie, four pump actuations)  \n  \nOld dropper device (being phased out):  \n  \n  * The dropper device delivers 0.5 mg/drop and the maximum daily dose of 20 mg is achieved with 40 drops  \n  \nHealthcare professionals should be aware of the correct use and administration of memantine pump device as outlined in the Summary of Product Characteristics. Healthcare professionals should also advise patients and their carers to carefully read the Patient Information Leaflet for memantine oral solution delivered by a pump device.\n\n  \nAdvice for healthcare professionals:  \n  \n  * There are differences in dose delivery between the pump device and dropper device for memantine  \n  * One actuation of the pump device delivers 0.5 mL of solution, corresponding to 5 mg memantine. The maximum daily dose is 20 mg or four pump actuations, whereas 40 drops could be given with the dropper  \n  * Please be vigilant regarding dose delivery for memantine products, particularly during the transition period from the dropper device to the new pump device. We request that you also advise patients and their caregivers:  \n  *     * how to use the new pump device to deliver the prescribed dose  \n    * to carefully read the Patient Information Leaflet for memantine oral solution delivered by a pump device  \n   \n  \nA [letter has been sent to healthcare professionals](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON099712) in October 2010 with information on this risk. Further information for patients can be found in the memantine Patient Information Leaflet.\n\n## Reporting of suspected adverse reactions\n\nPlease report any suspected adverse reactions associated with the use of  memantine on a Yellow Card ([www.yellowcard.gov.uk](http://www.yellowcard.gov.uk/)). Patients and caregivers can also report any suspected reactions to us via the Yellow Card Scheme.\n\n \n\nArticle citation: Drug Safety Update Nov 2010 vol 4, issue 4: A2.\n"
}